{"protocolSection":{"identificationModule":{"nctId":"NCT06717269","orgStudyIdInfo":{"id":"NX-5948-304"},"organization":{"fullName":"Nurix Therapeutics, Inc.","class":"INDUSTRY"},"briefTitle":"Relative Bioavailability of NX-5948 Tablets vs Capsules and the Effect of Covariates on the PK of NX-5948 Tablets","officialTitle":"A Phase 1, Open-Label Study in Healthy Volunteers to Evaluate the Relative Bioavailability of NX-5948 Tablets Compared to Capsules, and the Effect of Food and an Acid-reducing Agent on the Pharmacokinetics of NX-5948"},"statusModule":{"statusVerifiedDate":"2026-02","overallStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2024-11-30","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2026-04","type":"ESTIMATED"},"completionDateStruct":{"date":"2026-08","type":"ESTIMATED"},"studyFirstSubmitDate":"2024-12-01","studyFirstSubmitQcDate":"2024-12-01","studyFirstPostDateStruct":{"date":"2024-12-04","type":"ACTUAL"},"lastUpdateSubmitDate":"2026-02-03","lastUpdatePostDateStruct":{"date":"2026-02-05","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Nurix Therapeutics, Inc.","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"This is a multiple part, multiple cohort study evaluating the relative bioavailability, food effect, and drug-drug interaction of NX-5948 in healthy volunteers."},"conditionsModule":{"conditions":["Healthy Volunteer"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1"],"designInfo":{"allocation":"NON_RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":18,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"NX-5948 tablet and capsule under fasted and fed conditions","type":"EXPERIMENTAL","interventionNames":["Drug: NX-5948"]},{"label":"NX-5948 tablet and capsule combined with esomeprazole under fasted conditions","type":"EXPERIMENTAL","interventionNames":["Drug: NX-5948","Drug: Esomeprazole"]}],"interventions":[{"type":"DRUG","name":"NX-5948","description":"Administered orally in tablet or capsule form","armGroupLabels":["NX-5948 tablet and capsule combined with esomeprazole under fasted conditions","NX-5948 tablet and capsule under fasted and fed conditions"]},{"type":"DRUG","name":"Esomeprazole","description":"Administered orally in capsule form","armGroupLabels":["NX-5948 tablet and capsule combined with esomeprazole under fasted conditions"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Assessment of PK parameters: NX-5948 tablets versus capsules","description":"Relative bioavailability of NX-5948 tablet, compared to capsule, will be measured using PK parameters (AUC)","timeFrame":"9 weeks"},{"measure":"Assessment of PK parameters: NX-5948 tablets versus capsules","description":"Relative bioavailability of NX-5948 tablet, compared to capsule, will be measured using PK parameters (Cmax)","timeFrame":"9 weeks"},{"measure":"Assessment of PK parameters NX-5948 tablets versus capsules","description":"Relative bioavailability of NX-5948 tablet, compared to capsule, will be measured using PK parameters (Tmax)","timeFrame":"9 weeks"},{"measure":"Food effect and effect of esomeprazole on AUC0-t for single-dose NX-5948 tablet","description":"Evaluate the effect of food and the effect of multiple doses of esomeprazole on the single-dose PK of NX-5948 tablet","timeFrame":"9 weeks"},{"measure":"Food effect and effect of esomeprazole on AUC0-inf for single-dose NX-5948 tablet","description":"Evaluate the effect of food and the effect of multiple doses of esomeprazole on the single-dose PK of NX-5948 tablet","timeFrame":"9 weeks"},{"measure":"Food effect and effect of esomeprazole on Cmax for single-dose NX-5948 tablet","description":"Evaluate the effect of food and the effect of multiple doses of esomeprazole on the single-dose PK of NX-5948 tablet","timeFrame":"9 weeks"}]},"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n* Healthy, adult, male or female 19-55 years of age\n* Continuous non-smoker who has not used nicotine and tobacco-containing products for at least 3 months prior to the first dosing\n* Body mass index (BMI) ≥ 18.0 and ≤ 32.0 kg/m2\n* Medically healthy with no clinically significant medical history, physical examination, clinical laboratory profiles, vital signs, or 12-lead safety ECGs at the screening visit, as deemed by the PI or designee\n* Understands the study procedures in the informed consent form (ICF) and be willing and able to comply with the protocol.\n\nKey Exclusion Criteria:\n\n* Mentally or legally incapacitated or has significant emotional problems at the time of the screening visit or expected during the conduct of the study\n* Clinically significant history or presence of respiratory, gastrointestinal, renal, hepatic, hematological, lymphatic, neoplastic myeloproliferative, neurological, cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological, dermatological, endocrine or connective tissue diseases or disorders\n* History of any gastrointestinal surgery or cholecystectomy that could impact the PK of NX-5948\n* History or presence of alcohol or drug abuse within the past 2 years\n* History or presence of hypersensitivity, angioedema, or idiosyncratic reaction to the study drug(s) or related compounds\n* History or presence of:\n\n  * Significant multiple and/or severe allergies, including anaphylactic reaction.\n  * Personal or family history of prolonged QT syndrome or family history of sudden cardiac death.\n  * Evidence of atrial fibrillation, atrial flutter, complete bundle branch block, Wolff Parkinson-White Syndrome, or cardiac pacemaker.\n  * Adrenal insufficiency.\n  * Skin infection.\n* Female volunteers of childbearing potential\n* Female volunteer with a positive pregnancy test\n* Positive results for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV) at the screening visit\n* Donation of blood or significant blood loss within 56 days prior to the first dosing\n* Plasma donation within 7 days prior to the first dosing\n* History or presence of clinically significant medical or psychiatric condition or disease in the opinion of the PI or designee.\n* Previous exposure to NX-5948.\n* Participation in another clinical study within 30 days or within 5 half-lives (if known), prior to the first dosing, whichever is longer. The 30-day window will be derived from the date of the last blood collection or dosing, whichever is later, in the previous study to Day 1 of Period 1 of the current study.","healthyVolunteers":true,"sex":"ALL","minimumAge":"19 Years","maximumAge":"55 Years","stdAges":["ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Angie Badgett, MBA","role":"CONTACT","phone":"402-437-6351","email":"angie.badgett@celerion.com"},{"name":"Allen Hunt, MD","role":"CONTACT","phone":"402-437-6351","email":"allen.hunt@celerion.com"}],"overallOfficials":[{"name":"Study Director","affiliation":"Nurix Therapeutics","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Celerion","status":"RECRUITING","city":"Lincoln","state":"Nebraska","zip":"68502","country":"United States","geoPoint":{"lat":40.8,"lon":-96.66696}}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-25"},"interventionBrowseModule":{"meshes":[{"id":"D064098","term":"Esomeprazole"}],"ancestors":[{"id":"D009853","term":"Omeprazole"},{"id":"D053799","term":"2-Pyridinylmethylsulfinylbenzimidazoles"},{"id":"D013454","term":"Sulfoxides"},{"id":"D013457","term":"Sulfur Compounds"},{"id":"D009930","term":"Organic Chemicals"},{"id":"D011725","term":"Pyridines"},{"id":"D006573","term":"Heterocyclic Compounds, 1-Ring"},{"id":"D006571","term":"Heterocyclic Compounds"},{"id":"D001562","term":"Benzimidazoles"},{"id":"D006574","term":"Heterocyclic Compounds, 2-Ring"},{"id":"D000072471","term":"Heterocyclic Compounds, Fused-Ring"}]}},"hasResults":false}